Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 ...

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and Livdelzi.

ProteinQure has generated data that PQ203 exhibits potent efficacy in multiple patient-derived xenograft (PDX) models including those resistant to Sacituzumab Govitecan (Trodelvy™), an antibody ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S. patients directly if the government goes ahead with plans to slash drug prices ...

Merck KGaA, the German science and technology group, lowered its full-year sales growth forecast as it grapples with a weaker dollar and a slowdown in its electronics business.

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Gemini Insurance is under fire after a $2.5 million settlement claim, with Merck and Jones Lang LaSalle demanding coverage for a workplace injury ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, has successfully closed the divestment of its global Surface Solutions business to Global New Material International Holdings ...